Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

Basit Öğe Kaydı
dc.contributor.authorEkici, Sinan
dc.contributor.authorEroğlu, Alper
dc.date.accessioned2024-07-12T21:40:49Z
dc.date.available2024-07-12T21:40:49Z
dc.date.issued2007en_US
dc.department[Belirlenecek]en_US
dc.description.abstractPurpose: To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). Patients and Methods: Efficacy data from a large randomized phase III study of GC versus MVAC were updated. Time-to-event analyses were performed on the observed distributions of overall and progression-free survival. Results: A total of 405 patients were randomly assigned: 203 to the GC arm and 202 to the MVAC arm. At the time of analysis, 347 patients had died (GC arm, 176 patjents; MVAC arm, 171 patients). Overall survival was similar in both arms (hazard ratio [HR] 1.09; 95% CI, 0.88 to 1.34; P = .66) with a median survival of 14.0 months for GC and 15.2 months for MVAC. The 5-year overall survival rates were 13.0% and 15.3%, respectively (P = .53). The median progression-free survival was 7.7 months for GC and 8.3 months for MVAC, with an HR of 1.09. The 5-year progression-free survival rates were 9.8% and 11.3%, respectively (P = .63). Significant prognostic factors favoring overall survival included performanca score (> 70), TNM staging MO v Ml), low/normal alkaline phosphatase level, number of disease sites (<= three). and the absence of visceral metastases. By adjusting for these prognostic factors, the HR was 0.99 for overall survival and 1.01 for progression-free survival. The 5-year overall survival rates for patients with and without visceral metastases were 6.8% and 20.9%, respectively. Conclusion: Long-term overall and progression-free survival after treatment with GC or MVAC are similar. These results strengthen the role of GC as a standard of care in patients with locally advanced or metastatic TCC.en_US
dc.identifier.endpage27en_US
dc.identifier.issn2147-2270
dc.identifier.issue3en_US
dc.identifier.startpage25en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7486
dc.identifier.volume6en_US
dc.identifier.wosWOS:000219334700005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Science
dc.language.isotren_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY08844
dc.titleLong-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder canceren_US
dc.typeEditorial
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu